Show simple item record

dc.rights.licenseReconocimiento 4.0 Internacional
dc.contributor.advisorRondón Herrera, Federico
dc.contributor.advisorPatricia Rojas, Angela
dc.contributor.authorDelgado Marrugo, Raul David
dc.coverage.temporal2016-2022
dc.date.accessioned2024-09-05T18:33:09Z
dc.date.available2024-09-05T18:33:09Z
dc.date.issued2024
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/86796
dc.descriptionilustraciones, diagramas, tablas
dc.description.abstractIntroducción: En pacientes con miopatías inflamatorias idiopáticas (MII) se han correlacionado autoanticuerpos y alelos HLA con fenotipos clínicos en diferentes regiones del mundo. Objetivo: Evaluamos las características inmunogénicas en una población de la ciudad de Bogotá, Colombia. Métodos: Estudio transversal de 68 pacientes con MII. Panel de 15 autoanticuerpos específicos y asociados a miositis. Se realizó determinación de alelos HLA-DQA1, DQB1, DR mediante técnica de reacción en cadena de la polimerasa en tiempo real. Resultados: La población del estudio tenía una edad media de 52,2 años, y el 73% de los participantes eran mujeres. En el grupo, los tipos de MII más frecuentemente observados fueron Dermatomiositis (DM) (58%), Polimiositis (PM) (25%), Síndrome Antisintetasa (ASyS) (5,8%), Miositis Necrotizante Inmunomediada (MNIM) (5,8%) y Miositis por Cuerpos de Inclusión (MCI) (4%). Se realizó un panel de autoanticuerpos en 23 pacientes. Los resultados mostraron que Mi-2 (52%) era el anticuerpo más prevalente relacionado con DM (83%), características clínicas Gottron (75%) y Heliotropo (58%) con HLA-DQB1*03 (50%); ASyS Jo-1 (7; 30%) relacionados con PM (85%), neumonía intersticial inespecífica (NINE) (14%) y HLA-DQB1*03 (28%); anticuerpos asociados a Ku (13%) relacionados con DM (66%), Gottron y Heliotropo (66%), NINE (33%) y HLA-DQB1*03 (33%) Conclusiones: Este es el primer estudio realizado en Colombia que determina alelos HLA y autoanticuerpos de miositis en pacientes con MII, se encontraron diferentes co-prevalencias entre las manifestaciones clínicas y el perfil inmunogénico, lo que permite conocer las características de la población en nuestra comunidad e incentiva la investigación para estudios con una población mayor (Texto tomado de la fuente).
dc.description.abstractIntroduction: In patients with idiopathic inflammatory myopathies (IIM) autoantibodies and HLA alleles have been correlated with clinical phenotypes in different regions worldwide. Aim: We evaluated immunogenic characteristics in a population from the city of Bogota, Colombia. Methods: A cross-sectional study of 68 patients with IIM. Panel of 15 specific and myositisassociated autoantibodies, determination of HLA-DQA1, DQB1, DR alleles was performed by real-time polymerase chain reaction technique. Results: The study population had a mean age of 52.2 years, with 73% of the participants being female. Among the group, the most frequently observed types of IIM were Dermatomyositis (DM) (58%), Polymyositis (PM) (25%), Antisynthetase Syndrome (ASyS) (5.8%), Immune-Mediated Necrotizing Myositis (IMNM) (5.8%), and Inclusion Body Myositis (IBM) (4%). Table 1 shows other clinical features. An autoantibody panel was performed on 23 patients. Results showed that Mi-2 (52%) was the most prevalent antibody, relating to DM (83%), clinical features Gottron′s (75%) and Heliotrope (58%) with HLA-DQB1*03 (50%); ASyS Jo-1 (7; 30%) related to PM (85%), Nonspecific interstitial pneumonia (NSIP) (14%) and HLA-DQB1*03 (28%); Ku-associated antibodies (13%) related to DM (66%), Gottron and Heliotrope (66%), NSIP (33%) and HLA-DQB1*03 (33%). Conclusions: This is the first study conducted in Colombia determining HLA alleles and myositis autoantibodies in patients with MI, different co-prevalences were found between clinical manifestations and immunogenic profile, which allows us to know the characteristics of the population in our community and encourages research for studies with a larger population.
dc.format.extent73 páginas
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.publisherUniversidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610 - Medicina y salud::616 - Enfermedades
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéutica
dc.titlePrevalencia y coprevalencia de los factores inmuno genéticos en pacientes con miopatías inflamatorias idiopáticas de un centro de tercer nivel de complejidad
dc.typeTrabajo de grado - Especialidad Médica
dc.type.driverinfo:eu-repo/semantics/doctoralThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Interna
dc.contributor.researchgroupBiología Celular y Autoinmunidad
dc.coverage.cityBogotá
dc.coverage.countryColombia
dc.description.degreelevelEspecialidades Médicas
dc.description.degreenameEspecialista en Medicina Interna
dc.description.methodsEstudio observacional corte transversal descriptivo. Pacientes >18 años con diagnóstico de miopatía inflamatoria probable o definitiva dado por los criterios EULAR/ACR 2017 en pacientes hospitalizados o que asistieron a consulta externa de reumatología en el Hospital Universitario Nacional, durante el periodo entre enero de 2016 a julio de 2022. Pacientes con miopatías inflamatorias probables o definitivas secundarias a procesos neoplásicos.
dc.identifier.instnameUniversidad Nacional de Colombia
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourlhttps://repositorio.unal.edu.co/
dc.publisher.facultyFacultad de Medicina
dc.publisher.placeBogotá, Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.referencesDamoiseaux J, Vulsteke JB, Tseng CW, Platteel ACM, Piette Y, Shovman O, et al. Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev. 2019 Mar 1;18(3):293–305.
dc.relation.referencesOldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies-a guide to subtypes, diagnostic approach and treatment. Clinical Medicine. 2017;17(4):322– 30.
dc.relation.referencesSmoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: An administrative claims analysis. BMC Musculoskelet Disord. 2012;13.
dc.relation.referencesMcHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018 May 1;14(5):290–302.
dc.relation.referencesPina Cruellas MG, Trindade Viana V dos S, Levy-Neto M, Carlos de Souza FH, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics. 2013 Jul;68(7):909–14.
dc.relation.referencesO’Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. Medicine. 2005 Nov;84(6):338–49.
dc.relation.referencesMiller FW, Chen W, O’Hanlon TP, Cooper RG, Vencovsky J, Rider LG, et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun. 2015 Oct 1;16(7):470–80.
dc.relation.referencesPatricia K, Castro V. Descripción de los anticuerpos, y manifestaciones clínicas de pacientes con polimiositis y dermatomiositis. 2014.
dc.relation.referencesRothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2016 Aug 1;75(8):1558–66.
dc.relation.referencesTieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol [Internet]. 2016;30(1):149–68. Available from: https://www.sciencedirect.com/science/article/pii/S1521694216300225
dc.relation.referencesMammen AL. Autoimmune Myopathies. Continuum (N Y) [Internet]. 2016;22(6):1852–70. Available from: www.ContinuumJournal.com
dc.relation.referencesMcGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics [Internet]. 2018 Oct 14;15(4):976–94. Available from: https://doi.org/10.1007/s13311-018-00676-2
dc.relation.referencesDalakas MC. Pathophysiology of inflammatory and autoimmune myopathies.Presse Med [Internet]. 2011;40(4, Part 2):e237–47. Available from: https://www.sciencedirect.com/science/article/pii/S0755498211000534
dc.relation.referencesHilton-Jones D. Inflammatory muscle diseases. Curr Opin Neurol [Internet]. 2001;14(5). Available from: https://journals.lww.com/coneurology/fulltext/2001/10000/inflammatory_muscle_diseases.7.aspx
dc.relation.referencesDimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Vol.32, Neurologic Clinics. W.B. Saunders; 2014. p. 595–628.
dc.relation.referencesHill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. The Lancet [Internet]. 2001 Jan 13;357(9250):96–100. Available from: https://doi.org/10.1016/S0140-6736(00)03540-6
dc.relation.referencesClark KEN, Isenberg DA. A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol [Internet]. 2018 Jan 1;25(1):13–23. Available from: https://doi.org/10.1111/ene.13357
dc.relation.referencesStenzel W, Goebel HH, Aronica E. Review: Immune-mediated necrotizing myopathies – a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol [Internet]. 2012 Dec 1;38(7):632–46. Available from: https://doi.org/10.1111/j.1365-2990.2012.01302.x
dc.relation.referencesGrable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve [Internet]. 2010 Feb 1;41(2):185–90. Available from: https://doi.org/10.1002/mus.21486
dc.relation.referencesNoguchi E, Uruha A, Suzuki S, Hamanaka K, Ohnuki Y, Tsugawa J, et al. Skeletal Muscle Involvement in Antisynthetase Syndrome. JAMA Neurol [Internet]. 2017 Aug 1;74(8):992–9. Available from: https://doi.org/10.1001/jamaneurol.2017.0934
dc.relation.referencesDalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol [Internet]. 2010;10(3):346–52. Available from: https://www.sciencedirect.com/science/article/pii/S1471489210000275
dc.relation.referencesSchmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn [Internet]. 2010 May 1;4(3):241–50. Available from: https://doi.org/10.1517/17530051003713499
dc.relation.referencesFrikha F, Saidi N, Snoussi M, Ben Salah R, Ben Ayed M, Daoud E, et al. Le syndrome des antisynthétases : à propos de quatre observations et revue de la littérature. Rev Pneumol Clin [Internet]. 2012;68(6):351–60. Available from: https://www.sciencedirect.com/science/article/pii/S0761841712000971
dc.relation.referencesBenveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol [Internet]. 2016;29(5). Available from: https://journals.lww.com/coneurology/fulltext/2016/10000/advances_in_serological_diagnostics_of.18.aspx
dc.relation.referencesBevilacqua JA, Earle N. Inflammatory myopathies. Vol. 29, Revista Medica Clinica Las Condes. Ediciones Doyma, S.L.; 2018. p. 611–21.
dc.relation.referencesLundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M de, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec 1;76(12):1955–64.
dc.relation.referencesNakashima R. Clinical significance of myositis-specific autoantibodies. Immunol Med [Internet]. 2018 Jul 3;41(3):103–12. Available from: https://doi.org/10.1080/25785826.2018.1531188
dc.relation.referencesZampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, et al. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol [Internet]. 2019;38(1):125–32. Available from: https://doi.org/10.1007/s10067-018-4267-z
dc.relation.referencesTemmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, et al. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis. Medicine (United States). 2019 May 1;98(20).
dc.relation.referencesPlatteel ACM, Wevers BA, Lim J, Bakker JA, Bontkes HJ, Curvers J, et al. Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. J Transl Autoimmun [Internet]. 2019;2:100013. Available from: https://www.sciencedirect.com/science/article/pii/S2589909019300139
dc.relation.referencesSelva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, GrauJunyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol [Internet]. 2018 Sep 1;17(9):816–28. Available from: https://doi.org/10.1016/S1474-4422(18)30254-0
dc.relation.referencesJoyce NC, Oskarsson B, Jin LW. Muscle Biopsy Evaluation in Neuromuscular Disorders. Phys Med Rehabil Clin N Am [Internet]. 2012;23(3):609–31. Available from: https://www.sciencedirect.com/science/article/pii/S1047965112000459
dc.relation.referencesStaron RS, Hagerman FC, Hikida RS, Murray TF, Hostler DP, Crill MT, et al. Fiber Type Composition of the Vastus Lateralis Muscle of Young Men and Women. Journal of Histochemistry & Cytochemistry [Internet]. 2000 May 1;48(5):623–9. Available from: https://doi.org/10.1177/002215540004800506
dc.relation.referencesWitt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016;23(5):218–26.
dc.relation.referencesBarsotti S, Lundberg IE. Current Treatment for Myositis. Curr Treatm Opt Rheumatol. 2018 Dec;4(4):299–315.
dc.relation.referencesSasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol [Internet]. 2018 Nov 2;28(6):913–21. Available from: https://doi.org/10.1080/14397595.2018.1467257
dc.relation.referencesRothwell S, Cooper RG, Lamb JA, Chinoy H. Europe PMC Funders Group Strategies for Evaluating Idiopathic Inflammatory Myopathy Disease Susceptibility Genes. 2015;16(10).
dc.relation.referencesSalazar-Villa G, Rodríguez-Prada C, Bonfante-Tamara M, Restrepo-Correa R, Rodríguez-Padilla LM, Mesa-Navas MA, et al. Clinical characterisation of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey. Revista Colombiana de Reumatologia. 2022 Jan 1;29(1):9–18.
dc.relation.referencesSantos VA, Aragón CC, Posso-Osorio I, Obando MA, Barrera T, Zamorano L, et al. Caracterización epidemiológica de pacientes con miopatía inflamatoria en un hospital de cuarto nivel en Cali, Colombia. Revista Colombiana de Reumatología [Internet]. 2022;29(1):83–8. Available from: https://www.elsevier.es/es-revistarevista-colombiana-reumatologia-374-articulo-caracterizacion-epidemiologicapacientes-con-miopatia-S0121812320301638
dc.relation.referencesBernal-Macías S, Fernández-Ávila DG, Rincón-Riaño DN, Gutiérrez JM, Rosselli D. Prevalence of inflammatory myopathies in Colombia: Demographic analysis from the National Health Registry 2012–2018. Revista Colombiana de Reumatología [Internet]. 2023;30(2):81–6. Available from: https://www.sciencedirect.com/science/article/pii/S0121812321001262
dc.relation.referencesValenzuela A, Torres M, Devés JD. Performance of the 2017 EULAR/ACR criteria for idiopathic inflammatory myopathies in a cohort of patients from Latin America. Medicine (United States). 2022 Oct 28;101(43):E31015.
dc.relation.referencesZamudio GL, Barbosa Cobos RE, Solorzano Ruiz A, Morales EL, Delgado Ochoa D. HLA class I and II alleles may influence susceptibility to adult dermatomyositis in a Mexican mestizo population. Int J Clin Rheumtol. 2018;13(2).
dc.relation.referencesArechiga T, Villareal M, Villafranca J, Perez I, Lozoya A, Delgado D. Seventeen myositis autoantibodies: serological profile of hispanic patients with idiopathic inflammatory myopathies. In BMJ; 2018. p. 1536.3-1537.
dc.relation.referencesNuño L, Nuño N, Joven B, Carreira P, Maldonado V, Larena C, et al. Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis. Vol. 13, Reumatol Clin. 2017.
dc.relation.referencesLeclair V, Galindo-Feria AS, Rothwell S, Kryštůfková O, Zargar SS, Mann H, et al. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies. EBioMedicine. 2023 Oct 1;96.
dc.relation.referencesSatoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Vol. 52, Clinical Reviews in Allergy and Immunology. Humana Press Inc.; 2017.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.decsMiotoxicidad
dc.subject.decsMyotoxicity
dc.subject.decsMiositis
dc.subject.decsMyositis
dc.subject.decsAutoanticuerpos
dc.subject.decsAutoantibodies
dc.subject.decsAnticuerpos Fosfo-Específicos
dc.subject.decsAntibodies, Phospho-Specific
dc.subject.proposalDermatomiositis
dc.subject.proposalPolimiositis
dc.subject.proposalAutoanticuerpos
dc.subject.proposalHLA
dc.subject.proposalDermatomyositis
dc.subject.proposalPolymyositis
dc.subject.proposalAutoantibodies
dc.title.translatedPrevalence and co-prevalence of immunogenetic factors in patients with idiopathic inflammatory idiopathic myopathies in a third level of complexity
dc.type.coarhttp://purl.org/coar/resource_type/c_db06
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/TD
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
dcterms.audience.professionaldevelopmentEstudiantes
dcterms.audience.professionaldevelopmentInvestigadores
dcterms.audience.professionaldevelopmentMaestros


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Reconocimiento 4.0 InternacionalThis work is licensed under a Creative Commons Reconocimiento-NoComercial 4.0.This document has been deposited by the author (s) under the following certificate of deposit